SPRYCEL (™) (dasatinib) SPRYCEL (dasatinib) has been issued marketing authorization with conditions for the treatment of adults with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. SPRYCEL(TM) (dasatinib) has been issued marketing authorization without conditions for the treatment of adults with:  Ph+ chronic, accelerated, or blast phase CML with resistance...Read More

Tasigna (™) (nilotinib) TASIGNA® is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. TASIGNA® is also indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myeloid leukemia (CML) in adult patients resistant to or intolerant of at...Read More

TEVA-IMATINIB is indicated for the treatment of adult and pediatric patients with newly diagnosed Ph+ CML in chronic, accelerated or blast phase or after failure of interferon therapy. TEVA-IMATINIB is also indicated for use as a single agent for induction phase therapy in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)....Read More

Thank you very much for taking the time to complete the survey! Importance of this Research This research is important because it helps to further our understanding of the patient experience in terms of quality of life while undergoing treatment for CML, and may help to create or refine programs and/or treatment plans to enhance...Read More

The Chronic Myelogenous Leukemia (CML) Society of Canada is pleased to provide open access to the paper, “Treating Chronic Myeloid Leukemia – Improving Management Through Understanding of the Patient Experience”. The paper is written by Cheryl-Anne Simoneau, BA, who is the president and chief executive officer of the Chronic Myeloid Leukemia Society of Canada. Writing and editorial support...Read More

The majority of CML patients in Canada today are treated with oral tyrosine kinase inhibitors (TKI’s).  There are currently (2015) seven TKI’s approved by health Canada for the treatment of CML patients in Canada. Click on the links below to learn the approved indications for the drugs use in CML and, in some cases, in...Read More

10/12/20: Patient group takes fight for access to cystic fibrosis medicines to the UN Human Rights Council Today is International Human Rights Day, the anniversary of the day the United Nations General Assembly adopted, in 1948, the Universal Declaration of Human Rights (UDHR). The UDHR is a milestone document that proclaims the inalienable rights which...Read More

The CML Society of Canada is happy to announce that we have partnered with many CML Patient Advocate groups around the world with the help of The Max Foundation to help bring greater awareness of the importance of PCR (Polymerase Chain Reaction) testing in CML. The “What is MY PCR?” campaign aims to increase awareness of the...Read More

The CML Society of Canada is very pleased to recognize the work of the Province of Ontario for prioritizing equitable access to treatments for CML patients and their treating physicians. We certainly hope that the news spreads so that other Provinces can join in. Emerging information in CML treatment highlights the critical need for patients...Read More

Quality of Life II survey –  The CML Society of Canada presented very preliminary findings from our Quality of Life II survey at the recent European School of Hematology (ESH) conference.  The poster was titled “Quality of Life Study II, The Journey of CML & Disease Management Through the Eyes of Patients”  Authors: Cheryl-Anne Simoneau,...Read More